Chemistry42
Generative AI for small molecule drug design and optimization
Software · Cloud SaaSCompany source
Company profile
About Insilico Medicine
Insilico Medicine is an end-to-end, clinical-stage AI-driven drug discovery company that uses generative AI and reinforcement learning to design novel drug candidates.
Company description Insilico Medicine official website
Primary marketGenerative AI & Healthcare Infrastructure
Commercial modelCommercial information available on request
Work at Insilico Medicine?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- Cancer (BRCA-mutant, MTAP deficient, ER+/HER2- breast cancer, mesothelioma, solid tumors)
- Chronic Kidney Disease (CKD)
- COVID-19 and coronavirus infections
- Fibrotic diseases (lung and kidney)
- Inflammatory Bowel Disease (IBD)
- Multiple sclerosis
- Neurodegenerative diseases
- Neuropathic pain
- Parkinson's disease
- Psoriasis
Who it serves
- Academic partners
- Biotech companies
- Pharmaceutical companies
- Research institutions
Deployment & integration
Cloud Saas · Other deployment with recorded integration context.
Geographic context
MarketsCanada · Global · Greater China (Hong Kong, Shanghai) · Middle East (Abu Dhabi) · United States
Company sourceOfficial website
Company milestones
Platform expansion
Named most innovative biotechnology company in the world 2024. Multiple drug candidates advancing to clinical stages. Established global presence across U.S., Greater China, Canada, and Middle East.
Partnerships
Recorded partners
- 10 of the top 20 global pharmaceutical companies (by 2021 sales)
- GlaxoSmithKline (GSK)
- Medicilon
- Top institutions and universities globally
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
Generative Biologics
AI platform for biologics and antibody design
Software · Cloud SaaSCompany source
inClinico
AI-powered clinical trial outcome prediction platform
Software · Cloud SaaSCompany source
Nach01
AI-discovered therapeutic program
Other · OtherCompany source
PandaOmics
AI-powered target discovery and disease modeling platform
Software · Cloud SaaSCompany source
PandaOmics Box
Packaged version of PandaOmics for target discovery
Software · Cloud SaaSCompany source
Pharma.AI
End-to-end generative AI platform for drug discovery and development
Platform · Cloud SaaSCompany source
PreciousGPT
AI assistant for drug discovery and scientific research
Software · Cloud SaaSCompany source
Science42: DORA
Large Language of Life Models (LLLMs) for scientific research
Software · Cloud SaaSCompany source
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
From physics-based intelligence to molecular design: linking mechanistic learning across scales.MedScience · Jul 24, 2026
NDRG1 expression in cancers confers dependence on DNA damage repair and sensitivity to quinacrine.Science signaling · Jul 21, 2026
Comprehensive multi-omic dissection and AI-prioritized target identification in inverted papilloma-associated sinonasal squamous cell carcinoma.NPJ precision oncology · Jul 10, 2026
Integrating AI and Causal Genetics to Prioritize Therapeutic Targets for Aging and Age-Related Diseases.Aging and disease · Jun 12, 2026
Lessons From Drug Discovery for Cryoprotective Agent Design: An AI-Oriented Perspective.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · Jun 11, 2026
The Multi-Faceted Landscape of TEAD Inhibition: a 2017-2025 Patent and Literature Review.Bioorganic chemistry · Jun 5, 2026
Clinical validation
Clinical-trial records
Study Evaluating ISM8207 in Participants With Advanced Solid Tumors and Relapsed/Refractory B-Cell LymphomaNCT06445517 · Sponsor · RECRUITING
Study of ISM5939 in Patients With Advanced and/or Metastatic Solid TumorsNCT06724042 · Sponsor · NOT YET RECRUITING
Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)NCT07687459 · Sponsor · NOT YET RECRUITING
Study Evaluating ISM5411 Administered Orally to Subjects With Active Ulcerative Colitis (BETHESDA)NCT07265570 · Sponsor · RECRUITING
A Phase 1, Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISM8969NCT07581431 · Sponsor · RECRUITING
Study of ISM3412 in Participants With Locally Advanced/Metastatic Solid TumorsNCT06414460 · Sponsor · RECRUITING
Regulatory
Regulatory records
No linked records are currently available.
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
Time and cost reduction
Significantly reducing the time and cost to bring life-saving medications to patients through AI-driven drug discovery
Pipeline advancement
Leading AIDD pipeline progress with multiple programs in Phase II, Phase I, and IND-enabling stages
10 of top 20 global pharmaceutical companies
Collaboration on AI-driven drug discovery using Pharma.AI platform
Established collaborations with 10 of the top 20 global pharmaceutical companies by 2021 sales
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
Feng Ren
co-CEO, CSO, Head of Drug R&D
Stephanie Tsang
Senior EA to Co-CEO & President | Head of Operations, Office of Alex Zhavoronkov, PhD (Co-CEO)
Jacki Russell
Founder of Anti-Ageing & Wellness
Carol Ann Satler, MD, PhD, FACC, FAHA, FAAP
Vice President Clinical Development
Luoheng Qin
Vice President of Chemistry
Halle Zhang
Vice President, Clinical Development - Oncology
Leah Liu
Global Head of Capital Markets, VP
谢亦谦
BD associate director
06 · Company updates
Updates from Insilico Medicine
Recent articles published on Insilico Medicine's official website.
End-to-End AI-Driven Design of a First-in-Class PKMYT1 PROTAC Using Chemistry42
Read on Insilico MedicineAutomated SAR Cliff Analysis
Read on Insilico MedicineScience42: DORA.Introducing the Draft Outline Research Assistant workflow
Read on Insilico MedicinePROTAC decomposition: Multi-stage linker extraction
Read on Insilico MedicineCovering Patent Holes: How LEGION Uses AI to Block Competition in Chemical Space
Read on Insilico Medicine07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Generative AI & Healthcare Infrastructure
Companies providing generative AI platforms, large language models (LLMs), foundation models, or broad AI infrastructure specifically designed for healthcare applications. These companies serve multiple clinical use cases across the health system rather than focusing on a single clinical application or disease area.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.